Cargando…

The clinical efficacy and safety of dapagliflozin in patients with diabetic nephropathy

OBJECTIVE: To investigate the clinical efficacy and safety of dapagliflozin in the treatment of diabetic nephropathy (DN). METHODS: A total of 120 DN patients admitted to our hospital from June 2017 to March 2020 were divided into control and experimental groups, with 60 cases in each group. The con...

Descripción completa

Detalles Bibliográficos
Autores principales:	Huang, Ying, Lu, Wen, Lu, Hongyun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8966174/ https://www.ncbi.nlm.nih.gov/pubmed/35351189 http://dx.doi.org/10.1186/s13098-022-00815-y

Ejemplares similares

Clinical Efficacy of Dapagliflozin in the Treatment of Patients with Diabetic Nephropathy and Its Effect on Proteinuria Level
por: Jin, Ze-Jun, et al.
Publicado: (2023)

Efficacy and safety of dapagliflozin or dapagliflozin plus saxagliptin versus glimepiride as add‐on to metformin in patients with type 2 diabetes
por: Müller‐Wieland, Dirk, et al.
Publicado: (2018)

Effıcacy and safety of dapagliflozin on diabetic patients receiving high-doses of insulin
por: Sertbas, Meltem, et al.
Publicado: (2019)

Study comparing the efficacy and renal safety for patients with diabetes switching from dapagliflozin to empagliflozin
por: Yang, Ai-Yu, et al.
Publicado: (2020)

Comparison of safety and efficacy of dapagliflozin and empagliflozin in type 2 diabetes mellitus patients in India
por: Varshney, Amit, et al.
Publicado: (2023)

Efficacy and safety of Ginkgo biloba for patients with early diabetic nephropathy: A protocol for systematic review and meta-analysis
por: Wang, Hongyun, et al.
Publicado: (2020)

Efficacy and Safety of Dapagliflozin in Patients With CKD Across Major Geographic Regions
por: Vart, Priya, et al.
Publicado: (2022)

Improved home BP profile with dapagliflozin is associated with amelioration of albuminuria in Japanese patients with diabetic nephropathy: the Yokohama add-on inhibitory efficacy of dapagliflozin on albuminuria in Japanese patients with type 2 diabetes study (Y-AIDA study)
por: Kinguchi, Sho, et al.
Publicado: (2019)

Efficacy and Safety of Dapagliflozin versus Liraglutide in Patients with Overweight or Obesity and Type 2 Diabetes Mellitus: A Randomised Controlled Clinical Trial in Tianjin, China
por: Zhaohu, Hao, et al.
Publicado: (2022)

Abstract 52: Clinical efficacy of dapagliflozin in patients with newly diagnosed type 2 diabetes
por: Patil, Surekha Mahesh
Publicado: (2022)

Clinical Parameters Affecting the Therapeutic Efficacy of SGLT-2—Comparative Effectiveness and Safety of Dapagliflozin and Empagliflozin in Patients with Type 2 Diabetes
por: Anton, Irina Claudia, et al.
Publicado: (2022)

Efficacy and safety of dapagliflozin plus saxagliptin vs monotherapy as added to metformin in patients with type 2 diabetes: A meta-analysis
por: Zhuang, Yan, et al.
Publicado: (2020)

A Comparison of the Pharmacokinetics and Safety of Dapagliflozin Formate, an Ester Prodrug of Dapagliflozin, to Dapagliflozin Propanediol Monohydrate in Healthy Subjects
por: Kim, Hyun Chul, et al.
Publicado: (2023)

Efficacy and safety of dapagliflozin as monotherapy in patients with type 2 diabetes mellitus: A meta-analysis of randomized controlled trials
por: Feng, Miao, et al.
Publicado: (2019)

Dapagliflozin: Cardiovascular Safety and Benefits in Type 2 Diabetes Mellitus
por: Saleem, Fatima
Publicado: (2017)

Retrospective Analysis of the Efficacy of Dapagliflozin in Patients with Type 2 Diabetes in a Primary Clinic in Korea
por: Park, Sang Hyun, et al.
Publicado: (2019)

Efficacy and Safety of Safflower Yellow in Early Diabetic Nephropathy: A Meta-Analysis
por: Jin, Xiuze, et al.
Publicado: (2019)

Efficacy and safety of dapagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in diabetes mellitus
por: Fioretto, Paola, et al.
Publicado: (2015)

Efficacy and safety of the SGLT2 inhibitor dapagliflozin in type 1 diabetes: A meta-analysis of randomized controlled trials
por: Huang, Yuxin, et al.
Publicado: (2021)

Efficacy and Renal Safety of Dapagliflozin in Patients with Type 2 Diabetes Mellitus Also Receiving Metformin: A Real-Life Experience
por: Scorsone, Alessandro, et al.
Publicado: (2018)

An integrated RNA sequencing and network pharmacology approach reveals the molecular mechanism of dapagliflozin in the treatment of diabetic nephropathy
por: Bai, Zhenyu, et al.
Publicado: (2022)

Safety and Efficacy of Adding Dapagliflozin to Furosemide in Type 2 Diabetic Patients With Decompensated Heart Failure and Reduced Ejection Fraction
por: Ibrahim, Ayman, et al.
Publicado: (2020)

Safety of Dapagliflozin in Patients with Type 2 Diabetes Mellitus in Saudi Arabia: A Post Authorization Safety Study
por: Alguwaihes, Abdullah M.
Publicado: (2021)

Efficacy and Safety of Dapagliflozin in Children With Inherited Proteinuric Kidney Disease: A Pilot Study
por: Liu, Jiaojiao, et al.
Publicado: (2021)

A Network Meta-Analysis of the Dose–Response Effects of Dapagliflozin on Efficacy and Safety in Adults With Type 1 Diabetes
por: Li, Yinhui, et al.
Publicado: (2022)

Efficacy and safety of eplerenone treatment for patients with diabetic nephropathy: A meta-analysis
por: Hu, Honglei, et al.
Publicado: (2022)

Safety and efficacy of dapagliflozin in patients with focal segmental glomerulosclerosis: a prespecified analysis of the dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial
por: Wheeler, David C, et al.
Publicado: (2021)

Efficacy and Safety of Dapagliflozin According to Frailty in Patients With Heart Failure: A Prespecified Analysis of the DELIVER Trial
por: Butt, Jawad H., et al.
Publicado: (2022)

Efficacy of Low-dose Dapagliflozin in Young People with Type 1 Diabetes
por: Urakami, Tatsuhiko, et al.
Publicado: (2023)

Efficacy and safety of rituximab in the treatment of membranous nephropathy: A systematic review and meta-analysis
por: Lu, WanJun, et al.
Publicado: (2020)

Efficacy and Safety of Sitagliptin Compared with Dapagliflozin in People ≥ 65 Years Old with Type 2 Diabetes and Mild Renal Insufficiency
por: Raji, Annaswamy, et al.
Publicado: (2020)

Differential pharmacology and clinical utility of dapagliflozin in type 2 diabetes
por: Papakitsou, Ioanna, et al.
Publicado: (2019)

Efficacy of Dapagliflozin Combined with Lifestyle Intervention in Obesity Control
por: Dai, Wenhui, et al.
Publicado: (2022)

Effects and Mechanisms of Dapagliflozin Treatment on Ambulatory Blood Pressure in Diabetic Patients with Hypertension
por: Hao, Zirui, et al.
Publicado: (2020)

Use of dapagliflozin in patients with advanced diabetic kidney disease
por: Park, Hyun Sun, et al.
Publicado: (2018)

Nephroprotective Effects of Dapagliflozin in Patients with Type 2 Diabetes
por: Iijima, Yasuhiro, et al.
Publicado: (2023)

Dapagliflozin Ameliorates Lipopolysaccharide Related Acute Kidney Injury in Mice with Streptozotocin-induced Diabetes Mellitus
por: Chi, Po-Jui, et al.
Publicado: (2022)

Long-Term Treatment with the Sodium Glucose Cotransporter 2 Inhibitor, Dapagliflozin, Ameliorates Glucose Homeostasis and Diabetic Nephropathy in db/db Mice
por: Terami, Naoto, et al.
Publicado: (2014)

Epigenetics in the pathogenesis of diabetic nephropathy: Epigenetics in the pathogenesis of diabetic nephropathy
por: Li, Xue, et al.
Publicado: (2021)

Dapagliflozin Modulates the Fecal Microbiota in a Type 2 Diabetic Rat Model
por: Yang, Mei, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_s40um3k2ph40tjeghi4mp62j9h